Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026)
Theravance Biopharma's (TBPH) quarterly Cash from Operations came in at 73279000.0 in Q1 2026, up 70.26% year-on-year from 43039000.0 in Q1 2025, and up 1308.43% on a QoQ basis from 6064000.0 in Q4 2025.
Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Cash from Operations data on file, last reported at 73279000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations rose 70.26% year-over-year to 73279000.0 in Q1 2026; TTM through Mar 2026 was 268781000.0, a 726.36% increase from a year earlier, with the FY2025 full-year figure at 238541000.0, up 2167.98% from the prior year.
- Cash from Operations for Q1 2026 stood at 73279000.0, up from 6064000.0 in the prior quarter.
- Over the last five years, Cash from Operations for TBPH reached as high as 208074000.0 in Q2 2025 and fell as low as 26069000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 15933117.65 across 5 years, with a median of 4415000.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 4812.89% in 2025 and fell as far as 572.28% in 2025.
- Year by year, Cash from Operations stood at 54913000.0 in 2022, then tumbled by 101.56% to 854000.0 in 2023, then decreased by 5.62% to 902000.0 in 2024, then plunged by 572.28% to 6064000.0 in 2025, then surged by 1308.43% to 73279000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 73279000.0 in Q1 2026, 6064000.0 in Q4 2025, and 6508000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | 73.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.28 Mn |
| Mar 31, 2026 | 73.28 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Dec 31, 2024 | -902,000.00 |
| Dec 31, 2024 | -902,000.00 |
| Sep 30, 2024 | -5.20 Mn |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Dec 31, 2023 | -854,000.00 |
| Dec 31, 2023 | -854,000.00 |